Media Coverage
Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xb3 TM-001 in Brain Cancer
Bioasis Technologies and testing services provider BioAgilytix will partner on the development and validation of bioanalytical methods to support and advance the xB3 -001 program, Bioasis’ lead candidate to treat HER2+ brain cancer.
